Navigation Links
Alfacell Provides Shareholder Update
Date:6/19/2009

allow the company to complete submission of a New Drug Application and if a New Drug Application submission is completed, uncertainty whether FDA will file or approve such application, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials or differences of opinion in interpreting the results of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media and Investor Contact:
    Charles Muniz
    Alfacell Corporation
    732-652-4525
    info@alfacell.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Alfacell Provides ONCONASE(R) NDA Submission Update
2. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
3. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
4. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
5. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
6. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
7. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
8. Alfacell Corporation to Present at UBS Global Life Sciences Conference
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014 Imprimis Pharmaceuticals, ... company dedicated to delivering high quality and novel medicines ... that Chief Executive Officer Mark Baum will ... Craig-Hallum Alpha Select Conference in New York City.  Mr. ... Go Dropless™ campaign in ophthalmology. The presentation is ...
(Date:9/16/2014)... YORK , Sept. 16, 2014  Relmada Therapeutics, ... for the treatment of chronic pain, announced today that ... Kettering Cancer Center (MSKCC) in a series of animal ... a new tamper-resistant, extended release form of levorphanol.  Gavril ... for these studies. Dr. Pasternak said, ...
(Date:9/16/2014)... , N.J. and NEW PROVIDENCE, N.J. , ... experts will present a paper on the critical elements ... oxygen storage and deliver systems at the American Society ... be held at the Chicago Sheraton Hotel and Towers ... Derrick West , program manager of Hospital ...
Breaking Medicine Technology:Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 2Linde Healthcare experts to present details on installation of medical oxygen storage and distribution systems at ASPE convention 3
... Cynosure, Inc. (Nasdaq: CYNO ), a leader ... non-invasive aesthetic applications, today announced that two of its ... have received key international regulatory clearances. ... the sale in Canada of the company,s SmoothShapes® XV ...
... 2011 Unilife Corporation ("Unilife" or the ... announced that it remains on schedule to commence initial ... and commence sales to pharmaceutical customers by the end ... Company successfully commissioned the cleanrooms at its state-of-the-art production ...
Cached Medicine Technology:Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 2Cynosure Receives International Marketing Clearances for New Cellulite, Laser Lipolysis Products 3Unilife on Schedule to Fill Initial Orders for Unifill Syringe 2Unilife on Schedule to Fill Initial Orders for Unifill Syringe 3
(Date:9/16/2014)... Tara Haelle ... News) -- About 14.5 million U.S. cancer survivors are ... the American Association for Cancer Research reported Tuesday. ... and include nearly 380,000 survivors of childhood cancer, according ... advances in prevention, identification, research and treatment of cancer ...
(Date:9/16/2014)... New York (PRWEB) September 16, 2014 ... ) filed against C.R. Bard, Inc. continue to ... in U.S. District Court, Southern District of West ... Order dated September 15, 2014, the Court has ... beneficial to the proceeding. The Order indicates that ...
(Date:9/16/2014)... Danny Dreyer, ChiRunning & ChiWalking founder ... events throughout the U.S. Dreyer is one of the ... taught a full circuit of nationwide workshops since 2004. ... tracks at his workshops so participants of all levels ... techniques. , Workshop schedule: , ,     September ...
(Date:9/16/2014)... One in five American men admits to using ... survey shows. A nationally representative study from ... is more prevalent than diabetes. This violence includes ... hitting, kicking, biting, choking, burning or threatening their ... Although abuse by high-profile professional athletes has recently ...
(Date:9/16/2014)... The Wistar Institute,s Meenhard Herlyn, D.V.M., D.Sc., is ... Program of Research Excellence (SPORE) grant, a prestigious ... researchers at Wistar and the University of Pennsylvania ... this SPORE is to translate fundamental laboratory discoveries ... melanoma and other skin cancers. , Melanoma is ...
Breaking Medicine News(10 mins):Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 2Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 3Health News:Targeted Drugs Among Successes Against Cancer, Says New Report 4Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 2Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 3Health News:Vaginal Mesh Lawsuit News: Discovery Conferences Scheduled for Federal Transvaginal Mesh Lawsuits Filed Against C.R. Bard, Bernstein Liebhard LLP Reports 4Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 2Health News:Join ChiRunning® Founder, Danny Dreyer, on Fall 2014 US Workshop 3Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 2Health News:Wistar and Penn Medicine collaborate on $12.1 million SPORE grant in melanoma 3
... disturbing implications for the government, pension companies and life ... warning that increases in longevity translate into bad news ... look after us when we are old; to make ... uncertain. , Kevin Dowd, Professor of Financial Risk Management ...
... 29th 2007 With the genomic revolution radical improvement ... cancer. This is of the utmost importance, since the ... detection. In a special issue of Disease Markers, published ... the identification and understanding of biomarkers for epithelial ovarian ...
... found incidentally during a CT scan, and the masses ... according to a recent study conducted by researchers at ... increased utilization of CT, we are frequently encountering findings ... scanned, the so called incidentalomas, of which adrenal masses ...
... winning program at the Best Practices in Consumer ... 25-26, 2008, WASHINGTON, Nov. 29 Today ... selected the finalists for its,inaugural Best Practices in ... attracted entries detailing,innovative and proven programs that are ...
... Revolutionary new intimacy creme aids women in greater ... Passion Parties, Inc. is excited to,add the new ... cornerstone of the Passion Parties product line complete ... the G-Spot Creme instills a,positive level of confident ...
... Signs contract with Best Medical International Inc., ... leading,provider of medical isotopes and radiopharmaceuticals, today signed ... its external beam,therapy and self-contained irradiator product lines. ... growth strategy to focus its resources on being ...
Cached Medicine News:Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 2Health News:URAC Names Medco as a Finalist in First-ever Best Practices in Consumer Empowerment and Protection Awards 3Health News:Passion Parties Hits the Spot 2Health News:MDS Nordion Divests Non Strategic Product Lines 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: